OBJECT: The preponderance of @entity1420 receptors (PRs) and the scarcity of @entity172 receptors (ERs) in @entity1653 are well known. The expression of PRs may relate to @entity5 grade and recurrence. @entity2008 are associated with @entity146 , recurrence, and progression. In this study, the authors focus on the prognostic implications of hormone receptors in @entity1653 to help determine the clinical and biological aggressiveness of @entity5 and their correlations with @entity2008 . METHODS: Two hundred thirty-nine @entity1 with @entity1653 were separated into three groups. Group 1 (PR-positive group) comprised @entity1 whose @entity1653 displayed expression of PRs alone. Group 2 (receptor-negative group) included @entity1 whose lesions did not have receptors for either @entity1420 or @entity172 . Group 3 (ER-positive group) included @entity1 whose @entity5 displayed expression of ERs. Clinical and histological findings, proliferative indices, @entity5 recurrence, and cytogenetic findings were analyzed by performing the Fisher exact test. Compared with the receptor-negative (Group 2) and ER-positive (Group 3) groups, the PR-positive group (Group 1) had a statistically significant lower proliferative index and a smaller number of @entity1 in whom there were aggressive histopathological findings or changes in karyotype. In Groups 1, 2, and 3, the percentages of cases with aggressive histopathological findings were 10, 31, and 33%, respectively; the percentages of cases with @entity2008 were 50, 84, and 86%, respectively; and the percentages of cases in which there initially was no @entity41 but recurrence was documented were 5, 30, and 27%, respectively. A statistically significant increase in the involvement of chromosomes 14 and 22 was identified in receptor-negative and ER-positive de novo @entity1653 , when compared with the PR-positive group. Abnormalities on chromosome 19 were statistically significantly higher in receptor-negative @entity1653 than in PR-positive @entity5 . CONCLUSIONS: The expression of the PR alone in @entity1653 signals a favorable clinical and biological outcome. A lack of receptors or the presence of ERs in @entity1653 correlates with an accumulation of qualitative and quantitative karyotype abnormalities, a higher proportional involvement of chromosomes 14 and 22 in de novo @entity5 , and an increasing potential for aggressive clinical behavior, progression, and recurrence of these lesions. Sex hormone receptor status should routinely be studied for its prognostic value, especially in female @entity1 , and should be taken into account in @entity5 grading. The initial receptor status of a @entity5 may change in progression or recurrence of @entity5 .

XXXX and @entity172 receptors: opposing prognostic indicators in @entity1653 .

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive behavior'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningiomas'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['Cytogenetic abnormalities', 'cytogenetic abnormalities', 'chromosomal abnormalities']
@entity1420 :: (MESH:D011374,Chemical) :: ['Progesterone']
